Safe Supply Streaming Co Ltd. Announces Closing of Acquisition of Drug Lab 118 Ltd
Toronto, Ontario--(Newsfile Corp. - November 20, 2024) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe...
Pharmaceutical
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression...
BioSyent Releases Financial Results for Q3 and YTD 2024
MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for...
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Unnatural Products Appoints Simon Bailey, Ph.D., as Chief Operating Officer and President of R&D
Simon Bailey, Ph.D., Chief Operating Officer and President of R&D, Unnatural Products SANTA CRUZ, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE)...
Enlivex Adopts Bitcoin Treasury Reserve Strategy
Nes-Ziona, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS)
Company is evaluating IMSB301 in a Phase 1 clinical trial in healthy volunteers and plans to move rapidly into Phase...
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials...
OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference
MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in...
BioSyent Declares Fourth Quarter 2024 Dividend
MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce...
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one...
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced...
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T...
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than...
Update on Clinical Milestone – CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed”...
Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
NESS ZIONA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients...
Avextra Portugal Unveils Advanced Breeding Program to Develop Proprietary THC and CBD Cultivars, Establishing a Key IP Pillar
Avextra Portugal launches an innovative in-house breeding program to develop proprietary cannabis varieties with specific, consistent and reproducible cannabinoid and...
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each...
OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development
OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development Oxford, UK...